Overview

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of QGE031 in Japanese atopic male subjects in order to determine the eligibility of Japanese patients in subsequent clinical studies.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals